ArticleCommunications biology2024
Investigating the causal associations between metabolic biomarkers and the risk of kidney cancer.
Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Comparison of sclero-embolization and surgical ligation for varicocele treatment: a systematic review and meta-analysis.World journal of urology · 2025Pooled it
- Genetic causal association between kidney stones and proton pump inhibitors.International urology and nephrology · 2026Article
- Association between Diagnostic History and Cancer Incidence within 5 Years: A Real-world Observational Analysis.Cancer research communications · 2026Observational
- ASO Author Reflections: The Complex Role of 5-Alpha Reductase Inhibitors in Bladder Cancer.Annals of surgical oncology · 2025Article
- Single-cell analysis reveal cell-type-specific RNA methylation patterns in breast cancer.The Journal of international medical research · 2025Article
- Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights from a Large-Scale Prospective Cohort Study.Annals of surgical oncology · 2025Article
- Lactate and Lactylation in AKI-to-CKD: Epigenetic Regulation and Therapeutic Opportunities.Cell proliferation · 2025Review
- Mendelian randomization identifies genetically predicted calorie dietary preference as causal risk factors for cancer.Discover oncology · 2025Article
- Multi-omics analysis unveiled fibroblast-mediated pathogenesis in male genital lichen sclerosus.Cell & bioscience · 2025Article
- 3-Hydroxybutyrate, a metabolite in sustaining neuronal cell vitality: a mendelian randomization and in vitro experimentation.Nutrition & metabolism · 2025Article
- Metabolic diseases in the East Asian populations.Nature reviews. Gastroenterology & hepatology · 2025Review
- Decoding coffee's chlorogenic acid: genetic-network pharmacology insights on kidney stones.Urolithiasis · 2025Article
- Identification of Six Cerebrospinal Fluid Metabolites Causally Associated with Anorexia Nervosa Risk: A Mendelian Randomization Analysis.International journal of molecular sciences · 2025Article
- Identifying potential drug targets for sepsis-related adult respiratory distress syndrome through comprehensive genetic analysis and druggability assessment.Journal of global health · 2025Article
- Causal Relationship Between Metabolic Traits and Risk of NSCLC: A Two-Sample Mendelian Randomization Analysis.Journal of Cancer · 2025Article
- Trends in global and national infertility and factors associated with primary infertile couples in recent middle-aged Chinese.PloS one · 2025Article
- Article
- Current approaches and outstanding challenges of functional annotation of metabolites: a comprehensive review.Briefings in bioinformatics · 2024Review
- Assessment of glycemic susceptibility across multiple urological and reproductive disorders.Diabetology & metabolic syndrome · 2024Article
- Does metformin really reduce prostate cancer risk: an up-to-date comprehensive genome-wide analysis.Diabetology & metabolic syndrome · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Metabolic reprogramming plays an important role in kidney cancer. We aim to investigate the causal effect of 249 metabolic biomarkers on kidney cancer from population-based data. This study extracts data from previous genome wide association studies with large sample size. The primary endpoint is random-effect inverse variance weighted (IVW). After completing 249 times of two-sample Mendelian randomization analysis, those significant metabolites are included for further sensitivity analysis. According to a strict Bonferrion-corrected level (P < 2e-04), we only find two metabolites that are causally associated with renal cancer. They are lactate (OR:3.25, 95% CI: 1.84-5.76, P = 5.08e-05) and phospholipids to total lipids ratio in large LDL (low density lipoprotein) (OR: 0.63, 95% CI: 0.50-0.80, P = 1.39e-04). The results are stable through all the sensitivity analysis. The results emphasize the central role of lactate in kidney tumorigenesis and provide novel insights into possible mechanism how phospholipids could affect kidney tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.